You are here

Global TB Guidelines, Policies and Plans

WHO Global Tuberculosis Report 2020

Oct 2020
WHO Global Tuberculosis Report 2020

The World Health Organization (WHO) has published a global TB report every year since 1997. The purpose of the report is to provide a comprehensive and up-to-date assessment of the status of the TB epidemic, and of progress in the response to the epidemic – at global, regional and country levels – in the context of global commitments and strategies. The report is based primarily on data gathered by WHO in annual rounds of data collection. In 2020, data were reported by 198 countries and territories that accounted for more than 99% of the world’s population and estimated number of TB cases.

Activating a Human Rights-Based Tuberculosis Response - A Technical Brief for Policymakers and Program Implementers

Jul 2020
Activating a Human Rights-Based Tuberculosis Response - A Technical Brief for Policymakers and Program Implementers

The concept of a human rights-based response to tuberculosis (TB) is relatively new. The century-old, medicalized approach to TB did not consider the rights of the individual in planning the response.

This Technical Brief is the first to provide guidance directly to policymakers and national TB programs to promote their understanding of human rights in the context of TB and to improve the interventions and programs accordingly.

With this Brief, we hope that policymakers, national TB program implementers, and communities affected by TB can come together to plan and implement interventions that uphold the dignity and human rights of all people affected by TB.

South African Community Rights and Gender Assessment

Jul 2020
South African Community Rights and Gender Assessment

In 2019, Stop TB Partnership supported 13 countries to roll out assessment tools to identify TB key and vulnerable population data gaps, human rights and gender barriers to accessing TB services and subsequent solutions to address inequalities to accessing TB prevention, treatment, care and support services. These tools include a Legal Environment Assessment (LEA), TB/HIV Gender Assessment, and Data for Action framework on TB Key, Vulnerable and Underserved Populations.

Country findings from these assessments are summarized for South Africa in this report. 

Treatment of Drug-Resistant Tuberculosis - An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline

Nov 2019
Treatment of Drug-Resistant Tuberculosis - An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline

Background:

The American Thoracic Society, U.S. Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America jointly sponsored this new practice guideline on the treatment of drug-resistant tuberculosis (DR-TB). The document includes recommendations on the treatment of multidrug-resistant TB (MDR-TB) as well as isoniazid-resistant but rifampin-susceptible TB.

WHO Global Tuberculosis Report 2019

Oct 2019
WHO Global Tuberculosis Report 2019

Tuberculosis (TB) is a communicable disease that is a major cause of ill health, one of the top 10 causes of death worldwide and the leading cause of death from a single infectious agent (ranking above HIV/AIDS). It is caused by the bacillus Mycobacterium tuberculosis, which  is  spread when people who are sick with TB expel bacteria into the air; for example, by coughing. It typically affects the lungs (pulmonary TB) but can also affect other sites (extrapulmonary TB).

WHO guidelines on tuberculosis infection prevention and control - 2019 update

Mar 2019
WHO guidelines on tuberculosis infection prevention and control - 2019 update

The World Health Organization has just issued updated WHO guidelines on TB infection prevention and control. These guidelines outline a new evidence-based framework that promotes the implementation of an integrated package of Infection Prevention & Control (IPC) interventions based on administrative, engineering, and respiratory protection controls. This will contribute to cutting transmission and reducing the burden of TB illness and death to reach the global targets of the End TB Strategy and the political declaration of the UN High Level meeting on TB.

Management of Multidrug-Resistant Tuberculosis in Children: A FIELD GUIDE - Sentinal Project

Feb 2019
Sentinal Project - Management of Multidrug-Resistant Tuberculosis in Children: A FIELD GUIDE

Multidrug-resistant (MDR) tuberculosis (TB) is a growing global health crisis; MDR-TB is defined TB disease caused by strains of Mycobacterium tuberculosis with in vitro resistance to at least isoniazid and rifampicin, and it is estimated there are more than five million people infected and sick with drug-resistant forms of TB in the world today. With the increasing use of the Xpert MTB/RIF® to detect both TB and rifampicin resistance, the term “rifampicin-resistant TB” (RR-TB) is increasingly used as well.

The Union Management of Diabetes Mellitus-Tuberculosis - A Guide to the Essential Practice

Jan 2019
The Union Management of Diabetes Mellitus-Tuberculosis - A Guide to the Essential Practice

Diabetes mellitus (DM) increases the risk of tuberculosis (TB) by 2–3 times and increases the risk of adverse TB treatment outcomes. TB causes “stress-induced hyperglycaemia” and this can make the management of DM more difficult. A published “Collaborative Framework for the Care and Control of Tuberculosis and Diabetes” can guide policy makers and implementers in combatting the epidemics of both diseases.

Nursing Guide for Managing Side Effects to Drug-resistant TB Treatment

Dec 2018
Nursing Guide for Managing Side Effects to Drug-resistant TB Treatment

Patients on treatment for drug-resistant tuberculosis (DR-TB) face many challenges, most notably difficult side effects such as nausea, hearing loss and fatigue that may impact the patient’s quality of life, capacity to work and ability to continue activities of daily living. Recent studies have identified medication side effects as a major factor for patients stopping treatment prematurely. The 2017 WHO Global TB Report noted a continued crisis related to treatment outcomes for drug-resistant TB with only 54% of patients successfully completing treatment in 2014.

Political declaration of the UN high-level meeting

Oct 2018

We, Heads of State and Government and representatives of States and Governments, assembled at the United Nations in New York on 26 September 2018, with a dedicated focus for the first time on the global tuberculosis epidemic, reaffirm our commitment to ending the tuberculosis epidemic globally by 2030 in line with the Sustainable Development Goals target, commit to ending the epidemic in all countries, and pledge to provide leadership and to work together to accelerate our national and global collective actions, investments and innovations urgently to fight this preventable and treatable disease, affirming that tuberculosis, including its drug - resistant forms, is a critical challenge and the leading cause of death from infectious disease...

Pages